Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Y-mAbs Therapeutics Announced New Clinical And Preclinical Data From Studies Evaluating Naxitamab And GD2-SADA, Respectively, In Neuroblastoma

Author: Nabaparna Bhattacharya | September 06, 2024 07:32am

Posted In: YMAB

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist